ITM–JPMorgan Chase: investor conference, 202501 supply service ITM presents at JP Morgan Healthcare Conference 2025

	Period	2025-01-13
	Region	San Francisco, CA
	Country	United States (USA)
	Partner, 1st	ITM Isotope Technologies Munich SE
	Today	Isotopen Technologien München AG
	Group	ITM (Group)
	Partner, 2nd	J.P. Morgan Securities LLC
	Group	JPMorgan Chase (Group)
	Product	J.P. Morgan 43rd Annual Healthcare Conference 2025 San Francisco
	Product 2	RADIOPHARMACEUTICAL (RPT)
	Person	Cavey, Andrew (ITM Isotope Technologies Munich 202409– CEO before BMS + Novartis)
	Person 2	Maleck, Klaus (ITM 202309 CFO before TETEC AG + Evotec + BioGeneriX)

ITM Isotope Technologies Munich SE. (12/13/24). "Press Release: ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference". Garching / Munich.

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that its Chief Executive Officer, Dr. Andrew Cavey and Chief Financial Officer, Dr. Klaus Maleck will participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Dr. Andrew Cavey will present a corporate overview on Monday, January 13, 2025, at 11:30 am PST in the Mission Bay Room (32nd Floor) at The Westin St. Francis.

For further information, please contact:

Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: [email protected]

Corporate Communications
Kathleen Noonan / Julia Westermeir
Phone: +49 89 329 8986 1500
Email: [email protected]

ITM Isotope Technologies Munich SE

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com